Major good news! Zhengqing Haiqin has officially been granted a Pharmaceutical Production License (Class B), marking the start of a new chapter in its internationalization journey!

A single certificate carries the immense weight of strategic implementation.

Since its establishment in August 2024, Zhengqing Haiqin has shouldered the strategic mission of its parent company, Hunan Zhengqing Pharmaceutical Group: to leverage the Greater Bay Area as a base for building a “new hub of scientific and technological innovation” and a “bridgehead for global expansion.”

The approval of this Class B license not only serves as strong validation of the company’s strategic execution capabilities, but also marks the transition of the “Three Plus One” strategic framework from blueprint to reality:

Deeply cultivating technological research and development: The company has already developed sustained-release formulations, topical transdermal preparations, In situ gel injectable It has also established a comprehensive presence in cutting-edge fields such as nanocrystal formulations, injecting strong momentum into its future product pipeline.

Deepening Academician Cooperation: By co‑building platforms and sharing resources with leading teams of academicians, we focus on developing novel dosage forms and expanding therapeutic indications, thereby translating scientific expertise into groundbreaking innovations.

Expanding Overseas Operations: Leveraging Hengqin’s unparalleled geographical advantages, we are actively paving the way for Chinese medicine to go global, making the dream of bringing traditional Chinese medicine to the world within reach.

Empowering Technology Commercialization: We not only build momentum for our own growth but also incubate new products and health‑related offerings for the Group, driving the efficient translation of innovation into value and fostering synergistic development.

Deeply cultivating the Greater Bay Area to build an international hub of innovation.

As a shining achievement of the strategic cooperation between the Huaihua Municipal People’s Government and the Guangdong–Macao Traditional Chinese Medicine Science and Technology Industrial Park, Since its inception, Zhengqing Haiqin has been deeply rooted in the DNA of “openness” and “innovation.”

Location advantage: close to the water, naturally favored. The company is located in the picturesque Hengqin, facing Macao across the water. Situated at the heart of the Guangdong–Hong Kong–Macao Greater Bay Area, it serves as a cutting-edge gateway for connecting global resources. By fully leveraging policy advantages and international resources, we are accelerating the international registration process for innovative traditional Chinese medicine products, thereby sharing the unique value of TCM with the world.

Joint platform development, pooling strengths to achieve greater power: Backed by the robust “Hunan Provincial Innovation Center for Technological Advancements in Modern Traditional Chinese Medicine Manufacturing Processes,” the company is steadily strengthening its capabilities across four key areas: resource integration, quality control, R&D innovation, and product development. At present, the company is simultaneously advancing multiple generic drugs and innovative traditional Chinese medicines, while also pursuing the development of dozens of Class 1 and Class 2 new drugs within the group, gradually unfolding an ambitious vision of innovation.

System upgrade, safeguarding quality throughout the entire lifecycle.

Obtaining Certificate B entails a profound responsibility: ensuring the quality of pharmaceutical products throughout their entire lifecycle, from research and development to market launch. To honor this commitment, we spent more than a year building a compliant quality management system from the ground up:

1. Organizational Structure, Seamless Integration: The company has established a comprehensive set of functional departments covering scientific and technological R&D, production operations, quality management, pharmacovigilance, and sales development, ensuring that every stage—from the laboratory to the patient—is safeguarded by dedicated expert teams.

2. Compliance Framework, Benchmarking Against International Standards: The company adheres rigorously to world-class international standards and has established a comprehensive, science-based management system that covers the entire value chain, including drug registration, on-site inspections, and quality control.

3. New drug development, empowered by science and technology: The company focuses on core compounds and boldly integrates cutting-edge technologies such as AI‑driven drug discovery, accelerating the design and evaluation of lead compounds and infusing traditional Chinese medicine with a technological ethos.

Looking ahead, let us jointly build a new era of splendor for traditional Chinese medicine.

“The issuance of Drug Production License Type B is not the end, but a new beginning.” We are deeply inspired and feel an even greater sense of responsibility.

Looking ahead, Zhengqing Haiqin will steadfastly uphold its two core missions:

Becoming a practitioner of the modernization of traditional Chinese medicine: By leveraging modern science and technology to decode the profound therapeutic effects of traditional Chinese medicine, we are committed to developing more original innovative drugs of significant clinical value, ensuring that this ancient wisdom continues to shine brightly within the halls of contemporary medicine.

Becoming a pioneer in the international market: Expand into overseas markets and become a pioneer in the international arena: Leveraging Hengqin as a strategic hub, we connect with global markets, align with international standards and resources, and bring “China’s premium medicines”—imbued with Eastern wisdom—to the world.